Nippon Kayaku Gets Japanese Approval Of Hycamtin For Pediatric Malignant Solid Tumors
This article was originally published in PharmAsia News
Executive Summary
Nippon Kayaku’s Hycamtin obtained approval in Japan for the additional indication of pediatric malignant solid tumors, the company announced on June 14.